Partnerships between suppliers of customized organic-chemical syntheses for the early development stages of active pharmaceutical ingredients will take center stage at the BOS cmc industry forum, on the
SOCMA’s second annual Washington Fly-In, revolved around topics of teauthorizing chemical security rules, modernizing the Toxics Substances Control Act, and protecting workers’ rights threatened by Card Check discussed
Halozyme, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, has announced that Roche has selected a fifth exclusive target under the existing license and collaboration
Arete has announced the presentation of three posters of AR9281, an orally-administered soluble epoxide hydrolase (sEH) inhibitor, which is in a Phase II clinical program. The drug will
GlaxoSmithKline has announced that it has entered into an agreement to form a new joint venture with Shenzhen Neptunus Interlong. The latter is focused on developing and manufacturing
Abbott has launched the EAS Myoplex Strength Formula nutrition shake, designed to help sportsmen and fitness seekers refuel after physical activity. The ready-to-drink sports nutrition shake comes in
BioMarin has declared results from the Phase-I clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), for the treatment of phenylketonuria (PKU). The company expects to initiate the
Penwest, Endo and Valeant have announced that Endo has signed an exclusive license with Valeant allowing it to market Opana Er in Canada, Australia and New Zealand. Opana
Morphotek announced that FDA has cleared its investigational new drug (IND) application to study MORAb-004, for the treatment of patients with solid tumors. MORAb-004 targets endosialin, a protein
Pharmasset has announced the completion of the single ascending dose study, and has begun dosing in a multiple ascending dose trial with PSI-7851. Its a nucleotide analog polymerase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.